**Review Article**

Indian J Med Res 134, October 2011, pp 552-560

Invasive & non-invasive approaches for prenatal diagnosis of haemoglobinopathies: Experiences from India

R.B. Colah, A.C. Gorakshakar & A.H. Nadkarni

*National Institute of Immunohaematology (ICMR), Mumbai, India*

Received October 29, 2010

The thalassaemias and sickle cell disease are the commonest monogenic disorders in India. There are an estimated 7500 - 12,000 babies with β-thalassaemia major born every year in the country. While the overall prevalence of carriers in different States varies from 1.5 to 4 per cent, recent work has shown considerable variations in frequencies even within States. Thus, micromapping would help to determine the true burden of the disease. Although screening in antenatal clinics is being done at many centres, only 15-20 per cent of pregnant women register in antenatal clinics in public hospitals in the first trimester of pregnancy. There are only a handful of centres in major cities in this vast country where prenatal diagnosis is done. There is considerable molecular heterogeneity with 64 mutations identified, of which 6 to 7 common mutations account for 80-90 per cent of mutant alleles. First trimester foetal diagnosis is done by chorionic villus sampling (CVS) and DNA analysis using reverse dot blot hybridization, amplification refractory mutation system (ARMS) and DNA sequencing. Second trimester diagnosis is done by cordocentesis and foetal blood analysis on HPLC at a few centres. Our experience on prenatal diagnosis of haemoglobinopathies in 2221 pregnancies has shown that >90 per cent of couples were referred for prenatal diagnosis of β-thalassaemia after having one or more affected children while about 35 per cent of couples were referred for prenatal diagnosis of sickle cell disorders prospectively. There is a clear need for more data from India on non-invasive approaches for prenatal diagnosis.

**Key words** Haemoglobinopathies - India - invasive and non-invasive approaches - prenatal diagnosis

**Introduction**

The inherited disorders of haemoglobin are the most common monogenic disorders globally. Around 7 per cent of the population worldwide are carriers with more than 3,00,000 severely affected babies born every year.

Prenatal diagnosis is an integral component of a community control programme for haemoglobinopathies. Estimating the disease burden, generating awareness in the population, screening to identify carriers and couples at-risk and genetic counselling are prerequisites for a successful prevention programme. The remarkable success of such programmes in the 1970s in Cyprus, Italy, Greece and the UK led to the development of control programmes in many other countries.

**The extent of the problem in India**

β-thalassaemia has been reported in most of the communities that have been screened so far in India. While the overall prevalence varies from 1.5 to 4 per
cent in different States, communities like Sindhis, Punjabis, Lohanas, Kutchi Bhanushalis, Jains and Bohris have a higher prevalence (4-17%). Different reports have estimated that 7500-12,000 β-thalassaemia major babies would be born in India each year. It has also been shown recently by micromapping at the district level in two States, Maharashtra and Gujrat in western India that the prevalence of β-thalassaemia trait in different districts within these States is variable (0 - 9.5%). Based on these estimates there would be around 1000 births of β-thalassaemia major babies each year in these two States alone. Thus, such data should be obtained from different States to know the true burden of the disease and for planning and executing control programmes.

Haemoglobin S (Hb S) is prevalent in central India and among the tribal belts in western, eastern and southern India, the carrier rates varying from 1-40 per cent. It has been estimated that over 5000 babies with sickle cell disease would be born each year.

Haemoglobin E is widespread in the north eastern States in Assam, Mizoram, Manipur, Arunachal Pradesh and Tripura, the prevalence of Hb E trait being highest (64%) among the Bodo-Kacharis in Assam and going up to 30-40 per cent in some other populations in this region. In eastern India the prevalence of Hb E trait varies from 3-10 per cent in West Bengal. Both Hb E and Hb S when co-inherited with β-thalassaemia result in a disorder of variable clinical severity.

These inherited haemoglobin disorders cause considerable pain and suffering to the patients and their families and are a major drain on health resources in the country.

The need for accurate identification of carriers and couples at risk

Classical β-thalassaemia carriers have typically reduced red cell indices [mean corpuscular volume (MCV)<80 fl, mean corpuscular haemoglobin (MCH)<27 pg] with high RBC counts and elevated HbA2 levels (4-8%). However, a few β-thalassaemia heterozygotes fail to manifest these classical haematological features and are termed as silent carriers or normal HbA2 β-thalassaemia carriers. Individuals with borderline HbA2 levels (3.3 to 3.9%) need to be evaluated carefully to avoid a misdiagnosis. Mutations in the promoter region of the β-globin gene like -86 (C→G), -87 (C→G), -88 (C→T), -101 (C→T) as well as the capsite +1 (A→C) and the poly A (T→C) mutation can lead to borderline Hb A2 levels. Among these, the capsite +1 (A→C) mutation is seen in 1-2.5 per cent of β-thalassaemia heterozygotes in India. Other factors like associated α-thalassaemia or δ-thalassaemia and iron deficiency anaemia may also contribute in reduction of HbA2 levels.

It is also important to identify carriers of δβ-thalassaemia as compound heterozygotes of δβ-thalassaemia and β-thalassaemia can lead to a severe disorder. δβ-thalassaemia carriers are characterized by a modest elevation in Hb F levels (5-20%) with reduced or normal HbA2 levels and hypochromic and microcytic red cells. This phenotype partially overlaps with that of carriers of hereditary persistence of foetal haemoglobin (HPFH) and genotyping of high Hb F determinants is required as these are not infrequent in India. The common determinant of δβ-thalassaemia in India is the Asian Indian deletional inversion Gγ(Aγδβ)° thalassaemia.

The most appropriate time to screen

Screening in antenatal clinics is the best way to identify couples at immediate risk of having an affected child. However, experiences in India have shown that only 15-20 per cent of pregnant women come to antenatal clinics in public hospitals in the first trimester of pregnancy when prenatal diagnosis should ideally be done. This emphasizes the need for generating awareness in the population for early registration in antenatal clinics as well as among obstetricians to ask for a screening for β-thalassaemia and other haemoglobinopathies along with other investigations which are done routinely. The other target groups for screening in India include high school children, college or university students, high risk communities and extended family members of affected children.

The latter cascade screening approach appears to be a practical way of identifying a larger number of β-thalassaemia carriers in a cost-effective way in India. The large size of families as well as the system of living in joint families rather than nuclear ones is an advantage in this approach.

Genetic counselling

Genetic counselling plays a major role in a prevention programme. The Indian population comprises several ethnic groups with considerable cultural and religious diversity and this has to be kept in mind while counselling families to avoid social stigmatization. The influence of elders in the family also weighs heavily and has to be dealt with appropriately. While earlier, parents with a thalassaemia major child kept to
themselves, today their relatives and extended families are coming forward to get screened\textsuperscript{38}. There is only one centre in Lucknow in north India which offers a formal course for genetic counsellors and there is a need for more such courses throughout the country.

Counsellors should be aware that couples at risk of having a child with β-thalassaemia major, sickle cell disease, Hb S β-thalassaemia, Hb E β-thalassaemia, δβ - β-thalassaemia, Hb Lepore β-thalassaemia and Hb SD disease should be given the option of prenatal diagnosis to avoid the birth of a child with a severe disorder. However, couples at risk of having a child with Hb D disease, Hb D β-thalassaemia and Hb E disease do not require prenatal diagnosis as these disorders are mild.

In Sardinia, identification of the maximum number of carriers followed by effective genetic counselling helped to reduce the birth rate of β-thalassaemia major babies from 1:250 to 1:4000\textsuperscript{39}.

**Prenatal diagnosis**

**The first initiatives in India**

Facilities for prenatal diagnosis became available in India in the mid 1980s\textsuperscript{40}. Until then, although prenatal diagnosis was offered by a few centres, foetal samples were sent to the UK and other countries for analysis. Foetal blood sampling by foetoscopy done between 18 and 22 wk gestation and diagnosis by globin chain synthesis were done for the next 4 to 5 years at 2 centres in Mumbai\textsuperscript{40,41}.

**Chorionic villus sampling and DNA analysis in the first trimester**

In the 1990s first trimester foetal diagnosis by chorionic villus sampling (CVS) and DNA analysis was established at 4-5 centres in the north in Delhi\textsuperscript{42}, in the west in Mumbai\textsuperscript{41,43,44} and in the south in Vellore\textsuperscript{45}. These services then expanded to other cities like Lucknow and Chandigarh in the north\textsuperscript{46,47}, and Kolkata in the east\textsuperscript{48}. However, these services are still limited to major cities where couples are referred to or CVS samples are sent from surrounding areas.

**Molecular analysis**

β-thalassaemia is extremely heterogeneous with more than 200 mutations described worldwide\textsuperscript{49}. In India, about 64 mutations have been characterized by studies done at different centres\textsuperscript{30,31,49-51} (Table I). Six to seven mutations [IVS 1-5 (G→C), 619 bp deletion, IVS 1-1 (G→T), Codon 8/9 (+G), Codons 41/42 (-CTTT),

<table>
<thead>
<tr>
<th>S.No</th>
<th>Type of mutation</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Transcriptional mutations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>-90 (C&gt;T)</td>
<td>β⁺</td>
</tr>
<tr>
<td>2.</td>
<td>-88 (C&gt;T)</td>
<td>β⁺</td>
</tr>
<tr>
<td>3.</td>
<td>-87 (C&gt;T)</td>
<td>β⁺</td>
</tr>
<tr>
<td>4.</td>
<td>-80 (C&gt;T)</td>
<td>β⁺</td>
</tr>
<tr>
<td>5.</td>
<td>-29 (A&gt;G)</td>
<td>β⁺</td>
</tr>
<tr>
<td>6.</td>
<td>-28 (A&gt;G)</td>
<td>β⁺</td>
</tr>
<tr>
<td>7.</td>
<td>-25 (A&gt;G)</td>
<td>β⁺</td>
</tr>
<tr>
<td>B. Cap site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>+1 (A&gt;C)</td>
<td>β⁺</td>
</tr>
<tr>
<td>C. Initiation codon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>ATG &gt; ACG</td>
<td>β⁰</td>
</tr>
<tr>
<td>D. RNA processing mutations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>i) Splice junction site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>IVS 1-5 (G&gt;C)</td>
<td>β⁺</td>
</tr>
<tr>
<td>2.</td>
<td>IVS 1-128 (TAG &gt; GAG)</td>
<td>?</td>
</tr>
<tr>
<td>3.</td>
<td>IVS II-837 (T&gt;G)</td>
<td>?</td>
</tr>
<tr>
<td>(ii) Consensus site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>IVS I-110 (G&gt;A)</td>
<td>β⁺</td>
</tr>
<tr>
<td>2.</td>
<td>IVS II-591 (T&gt;C)</td>
<td>β⁺</td>
</tr>
<tr>
<td>3.</td>
<td>IVS II-613 (C&gt;T)</td>
<td>β⁺</td>
</tr>
<tr>
<td>4.</td>
<td>IVS II-654 (C&gt;T)</td>
<td>β⁺</td>
</tr>
<tr>
<td>5.</td>
<td>IVS II-745 (C&gt;G)</td>
<td>β⁺</td>
</tr>
<tr>
<td>(iii) IVS changes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>IVS 1-29 (A&gt;C)</td>
<td>β⁺</td>
</tr>
<tr>
<td>2.</td>
<td>IVS 1-129 (A&gt;C)</td>
<td>β⁺</td>
</tr>
<tr>
<td>3.</td>
<td>IVS 1-130 (G&gt;C)</td>
<td>β⁺</td>
</tr>
<tr>
<td>4.</td>
<td>IVS 1-130 (G&gt;A)</td>
<td>β⁺</td>
</tr>
<tr>
<td>5.</td>
<td>IVS 1-130 (G&gt;A)</td>
<td>β⁺</td>
</tr>
<tr>
<td>6.</td>
<td>IVS 1-130 (G&gt;A)</td>
<td>β⁺</td>
</tr>
<tr>
<td>7.</td>
<td>IVS 1-130 (G&gt;A)</td>
<td>β⁺</td>
</tr>
<tr>
<td>8.</td>
<td>IVS II-1 (G&gt;A)</td>
<td>β⁺</td>
</tr>
<tr>
<td>(iv) Coding region changes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>Codon 26 (G&gt;A) Hb E</td>
<td>β⁺</td>
</tr>
<tr>
<td>E. RNA translational mutations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>i) Nonsense</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>Codons 4,5,6 (ACT, CCT GAG&gt; ACA TCT TAG)</td>
<td>β⁰</td>
</tr>
<tr>
<td>2.</td>
<td>Codon 5 (-CT), Codon 13 (C&gt;T), Codon 26 (G&gt;C), Codons 27/28 (+C) in cis</td>
<td>?</td>
</tr>
<tr>
<td>3.</td>
<td>Codon 6 (GAG &gt; TAG) and on the same chromosome Codon 4 (ACT&gt; ACA)</td>
<td>β⁰</td>
</tr>
<tr>
<td>4.</td>
<td>Codon 8 (A&gt;G)</td>
<td>?</td>
</tr>
<tr>
<td>5.</td>
<td>Codon 13 (C&gt;T), Codon 26 (G&gt;A), Codons 27/28 (-C) in cis</td>
<td>?</td>
</tr>
<tr>
<td>6.</td>
<td>Codon 15 (TGAG &gt; TAG)</td>
<td>β⁰</td>
</tr>
<tr>
<td>7.</td>
<td>Codons 62-64 (7 bp del)</td>
<td>β⁰</td>
</tr>
<tr>
<td>8.</td>
<td>Codons 81-87 (22 bp del)</td>
<td>β⁰</td>
</tr>
<tr>
<td>9.</td>
<td>Codon 121 (G&gt;T)</td>
<td>β⁰</td>
</tr>
</tbody>
</table>

Contd...
Codon 15 (G→A), Codon 30 (G→C)] are common accounting for 85-95 per cent of mutant alleles. However, regional differences in their frequencies have been noted\textsuperscript{30,31,49-51} (Fig. 1). The prevalence of IVS 1 -5 (G→C), the most common mutation in India varies from 15-88 per cent in different States. Codon 15 (G→A) is the second most frequent mutation in Maharashtra and Karnataka and Codon 5 (-CT) is the third most common mutation in Gujarat. The -88 (C→T) and the Cap site -1 (A→C) mutations are more common in the northern region\textsuperscript{30,31,50}. The 619 bp deletion is the most common mutation among the immigrant population from Pakistan.

This knowledge on the distribution of mutations in different regions and in people of different ethnic backgrounds has facilitated prenatal diagnosis using molecular techniques like covalent reverse dot blot hybridization (CRDB), amplification refractory mutation system (ARMS), denaturing gradient gel electrophoresis (DGGE), and DNA sequencing\textsuperscript{43,44,52}.

**Foetal blood analysis in the second trimester**

Most of the prenatal diagnosis programmes in the Mediterranean countries started with second trimester foetal blood analysis but they were able to switch over to first trimester diagnosis in a short span\textsuperscript{5,39}.

In India, second trimester diagnosis is still done as many couples at risk are identified late during pregnancy. Foetal blood sampling is done by cordocentesis at 18 to 20 wk gestation and after confirming that there is no maternal contamination in the foetal sample by foetal cell staining using the Kleihauer-Betke method, it is analysed by HPLC on the Variant Hemoglobin Testing System (Bio Rad Laboratories, Hercules, USA). The Hb A levels in foetuses affected with β-thalassaemia major have ranged from 0 to 0.5 per cent and these were distinguishable from heterozygous babies where the Hb A levels were >1.3 per cent in different studies. However, there was some overlap in Hb A levels between heterozygotes and normals\textsuperscript{53-55}. Sickle cell disease and Hb E thalassaemia have also been diagnosed in this way. On the other hand, experience in Thailand showed that while $\beta^0$ thalassaemia homozygotes and Hb E -$\beta^0$ thalassaemia compound heterozygotes could be diagnosed by HPLC analysis of foetal blood, $\beta^+\epsilon$ thalassaemia homozygotes may be misdiagnosed as heterozygotes\textsuperscript{56}.

Amniotic fluid cells have not been used extensively in India for prenatal diagnosis of haemoglobinopathies.
Experience at National Institute of Immunohaematology (NIIH), Mumbai

Both first and second trimester prenatal diagnosis for the β-thalassaemias and sickle cell disorders are done at National Institute of Immunohaematology, Mumbai, and over the last 25 years 2,221 pregnancies at risk have been investigated (Table II). While majority of the couples were at risk of having children with β-thalassaemia major, a significant number of couples at risk of having children with sickle cell disorders have been referred for prenatal diagnosis in the last 4 to 5 years. Our experience in western India has shown that there are still very few couples (<10%) who come prospectively in the first pregnancy for prenatal diagnosis of the β-thalassaemias while 25 - 35 per cent of couples come prospectively for prenatal diagnosis of sickle cell disorders. This is a reflection of the greater awareness in regions particularly in Maharashtra and Gujarat where sickle cell disorders are common. Realizing the need for more centres for prenatal diagnosis in the country, the Indian Council of Medical Research, New Delhi, is trying to establish regional centres with the help of NIIH, Mumbai, in Nagpur in Maharashtra, Valsad and Surat in Gujarat, Bangalore in Karnataka, Kolkata in West Bengal and Ludhiana in Punjab mainly in medical colleges.

Non-invasive prenatal diagnosis from maternal blood

Current methods for obtaining foetal genetic material like chorionic villus sampling, amniocentesis and cordocentesis are invasive procedures which are associated with a small risk of foetal loss even when done by experienced hands\(^{57}\). This has led to many studies on the possibility of accessing foetal cells from the maternal circulation for non-invasive diagnosis.

**Isolation of foetal cells from maternal blood**

Trophoblasts, lymphocytes and nucleated erythrocytes (NRBCs) were the 3 cell types used as a source of foetal DNA. Foetal NRBCs were most widely used as they are mononuclear, are specific to the ongoing pregnancy and can be detected in the first trimester. These express several antigens like transferrin receptor and produce foetal haemoglobin chains like zeta (ζ), epsilon (ε) and gamma (γ) which are useful markers\(^{58,59}\). However, their numbers in the maternal circulation during pregnancy are only a few. It is estimated that around 2 µl of foetal blood crosses into the maternal circulation per day in the first and second trimesters and 1/50,000 cells are of foetal origin. Thus enrichment of foetal NRBCs was done by density gradient centrifugation using percoll or ficoll and isolation of the cells by fluorescence activated cell sorting (FACS) or magnetic activated cell sorting (MACS) using different monoclonal antibodies or pick up of single NRBCs after staining by microdissection\(^{60}\).

A few reports were published on the non-invasive prenatal diagnosis of sickle cell anaemia and β-thalassaemia using foetal NRBCs and PCR based protocols\(^{61-63}\). The number of pregnancies studied were few and accurate diagnosis was not possible in every case.

**Our experience**

We attempted non-invasive prenatal diagnosis of β-thalassaemia major, sickle cell disorders and Hb E β-thalassaemia by isolating foetal NRBCs from 7 ml of maternal blood at different periods of gestation in 100 cases. As shown schematically in Fig. 2, after percoll density gradient centrifugation for enrichment of foetal NRBCs, a combination of 3 monoclonal antibodies CD 45, Glycophorin A (GpA) and anti-Hb F were used for flow sorting. The CD45 negative cells were first selected and from this population the cells which were dual positive for Glycophorin A and Hb F were sorted. Foetal NRBCs could be isolated between 9 and 22 wk gestation although maximum number of cells were obtained between 10 and 14 wk gestation. DNA was isolated from the sorted foetal NRBCs and a nested ARMS

<table>
<thead>
<tr>
<th>Couples at risk</th>
<th>No. of pregnancies</th>
<th>Affected foetuses</th>
<th>Prospective diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-thalassaemia major</td>
<td>1903</td>
<td>447 (23.5)</td>
<td>140 (7.4)</td>
</tr>
<tr>
<td>Sickle cell disease</td>
<td>207</td>
<td>50 (24.2)</td>
<td>72 (34.8)</td>
</tr>
<tr>
<td>Hb S-β thalassaemia</td>
<td>45</td>
<td>7 (15.6)</td>
<td>12 (26.7)</td>
</tr>
<tr>
<td>Hb E-β thalassaemia</td>
<td>46</td>
<td>9 (19.7)</td>
<td>12 (26.1)</td>
</tr>
<tr>
<td>β−δβ thalassaemia</td>
<td>16</td>
<td>5 (31.3)</td>
<td>0</td>
</tr>
<tr>
<td>Others (Hb SD disease , Hb Lepore - β thalassaemia)</td>
<td>4</td>
<td>1 (25.0)</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>2221</td>
<td>519 (23.4)</td>
<td>236 (10.6)</td>
</tr>
</tbody>
</table>
PCR approach was developed for the detection of 12 different mutations. The foetal genotype was correctly determined in 84 of the 100 cases (84%). In 10 cases, the diagnosis was incorrect due to maternal contamination in the flow sorted cells and in 6 cases this was due to non amplification of alleles\(^\text{64}\). In another 30 pregnancies substituting Glycophorin A by CD 71 increased the accuracy of diagnosis to 90 per cent. Thus, the problems of maternal contamination and allele dropouts remain.

**Circulatory foetal DNA in maternal plasma**

The discovery of cell free foetal DNA in maternal plasma by Lo et al\(^\text{65}\) opened up new avenues for non-invasive prenatal diagnosis. However, for the diagnosis of monogenic disorders like the thalassaemias, this approach is still a challenge as foetal DNA represents only 5 per cent of the DNA in maternal plasma\(^\text{66}\), although recently it has been shown to be present in higher concentrations (10-20\%)\(^\text{67}\). It was shown that foetal DNA fragments are smaller in size (<313 bp) than maternal DNA fragments (>1 kb) and cell free foetal DNA in maternal plasma can be enriched by size fractionation on agarose gels\(^\text{68}\). Most of the reports so far have been based on detection or exclusion of paternal \(\beta\)-thalassaemia mutations when the maternal and paternal mutations are different or on the efficacy of detection of informative single nucleotide polymorphisms (SNPs) linked to the paternal mutant or normal allele. The diagnostic methods used have included real time allele specific PCR, allele specific arrayed primer extension (AS-APEX) technology, conventional PCR - DGGE and MALDI-TOF mass spectrometry\(^\text{69-76}\).

The potential disadvantage of most of these studies is that only paternally inherited alleles can be studied and invasive procedures may still be required in many cases when the paternal mutation is present. Besides, the technology is sophisticated and would not be available at many diagnostic laboratories.

**Our experience with cell free foetal DNA analysis**

Fig. 3 shows the approach used by us for prenatal diagnosis using cell free foetal DNA from maternal plasma. In 30 couples where the paternal and maternal mutations were different, we extracted DNA from maternal plasma. After size separation on agarose gels a fragment of about 300 bp was excised and used for looking for the presence or absence of the paternal mutation by semi-nested PCR. An accuracy of 80 per cent was achieved (unpublished data).

**The future**

It has been predicted that within the next 10 years, the complete foetal genome from maternal plasma would be successfully sequenced. The main technology for non-invasive prenatal diagnosis even for monogenic disorders could be based on single molecule analysis methods. Digital PCR and massively parallel sequencing would be the technology used\(^\text{77}\).

**Acknowledgment**

Authors thank Drs D. Mohanty and K. Ghosh for their support, and are grateful to all their collaborating obstetricians and sonologists and their technical staff.

**References**


Reprint requests: Dr Roshan Colah, Scientist F, National Institute of Immunohaematology (ICMR), 13th Floor, NMS Bldg, KEM Hospital Campus, Parel, Mumbai 400 012, India
e-mail: colahrb@gmail.com